Search
News & Events
World-first nasal spray whooping cough vaccine aims to protect young bubsTiny babies could soon have much-needed protection from community transmission of potentially deadly whooping cough thanks to a world-first nasal spray vaccine being trialed at The Kids Research Institute Australia.
News & Events
The Kids Research Institute Australia researcher wins Eureka Prize for Emerging Leader in SciencePaediatric infectious disease expert and clinician-scientist Associate Professor Asha Bowen has been named as the Emerging Leader in Science at the country’s most prestigious science awards – the Australian Museum Eureka Prizes.
News & Events
WA’s nation-leading immunisation program for babies slashes RSV hospital admissionsAn Australian-first study demonstrating the effectiveness of a new immunisation against respiratory syncytial virus (RSV) for babies found it to be almost 90 per cent effective in reducing hospitalisation rates and helped more than 500 WA families avoid a hospital stay.
Research
Cardiac monitoring safety assessment framework for early phase group a streptococcal vaccine trialsThis paper presents a comprehensive cardiac safety framework for early clinical development of Streptococcus pyogenes (Group A Streptococcus) vaccines, endorsed by the Strep A Vaccine Global Consortium and the Australian Strep A Vaccine Initiative. Given historical concerns about vaccine-associated acute rheumatic fever, we have established standardized echocardiography protocols integrated with clinical assessment for monitoring cardiac safety in early-phase vaccine trials.
Research
Respiratory Syncytial Virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab ProphylaxisNirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.
Research
Factors influencing adult and adolescent completion of treatment for late syphilis: a mixed methods systematic reviewTo identify factors influencing the completion of a three-dose course of weekly intramuscular benzathine penicillin G injections by adults and adolescents with syphilis of unknown duration or late syphilis.
Research
What influences the implementation of health checks in the prevention and early detection of chronic diseases among Aboriginal and Torres Strait Islander people in Australian health careThis review aims to systematically identify contextual and mechanistic factors that contribute to the success or failure of implementing effective HCs in the prevention and early detection of chronic diseases among Aboriginal and Torres Strait Islander people in Australian primary health care (PHC).
Research
Optimisation of the sampling method for skin microbiome studies in healthy children: a pilot cohort studyRecent interest in the diverse ecosystem of bacteria, fungi and viruses that make up the skin microbiome has led to numerous studies investigating the skin microbiome in healthy skin and in dermatological conditions. However, skin microbiome analysis is challenging due to relatively low numbers of skin microorganisms compared to mucosal sites, such as the respiratory or gastrointestinal tracts. Microbiome results are heavily influenced by sampling methods.
Research
Net Promoter Score Model for Evaluating Paediatric Medicine Acceptability: Validation and Feasibility StudyMedicine acceptability is crucial for paediatric drug development, yet its assessment remains challenging due to the multifaceted nature of sensory attributes like taste, smell, and mouthfeel. Traditional methods of acceptability evaluation often involve complex questionnaires and lack standardisation, leading to difficulties in a comparative analysis across studies.
Research
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results from a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young AdultsMeningococcal serogroup B (MenB) strains are highly diverse. Breadth of immune response for the MenB vaccine, 4CMenB, administered at 0-2, 0-6, or 0-2-6 months, was demonstrated by endogenous complement-human serum bactericidal antibody (enc-hSBA) assay against an epidemiologically relevant panel of 110 MenB strains.